Not finding it? Sign in to also search OpenAlex live.
-
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +21 more
24citations -
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT2023 Bone Marrow Transplantation article Medicine Multiple Myeloma Research and Treatments Open access
Rémi Tilmont, Ibrahim Yakoub‐Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas PM Schaap, +20 more
2citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Jacob P. Laubach, Jonathan L. Kaufman, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +22 more
24citations -
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study2022 British Journal of Haematology article Medicine Multiple Myeloma Research and Treatments Open access
Douglas Weston Sborov, Muhamed Baljević, Brandi Reeves, Jacob P. Laubach, Yvonne Adeduni Efebera, Cesar Rodriguez, +15 more
24citations -
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Larry Don Anderson, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, +21 more
3citations -
Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view2021 Expert Review of Anticancer Therapy article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Frederick W.F. Thielen, Marie José Kersten, Pim Kuizenga, Mels Hoogendoorn, Eduardus F. M. Posthuma, Wendy BC Stevens, +2 more
3citations -
Cost-Effectiveness of Lenalidomide Plus Rituximab Versus Rituximab Monotherapy in Patients with Previously Treated Follicular Lymphoma2020 Research Square preprint Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Frederick W.F. Thielen, Marie José Kersten, Pim Kuizenga, Mels Hoogendoorn, Eduardus F. M. Posthuma, Wendy BC Stevens, +2 more
0citations -
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Uta Bertsch, Roland R. Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, +26 more
160citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
Sonja Zweegman, Thierry T.F. Facon, Vânia Hungria, Nizar Jacques Bahlis, Christopher Paul Venner, Marc Justin Braunstein, +22 more
13citations -
Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.2024 Journal of Clinical Oncology conference-abstract Medicine Lymphoma Diagnosis and Treatment Open access
Leslie A. Lori, Lorenzo Falchi, Joost S.P. Vermaat, Gerardo Musuraca, David Belada, Marcel Nijland, +8 more
9citations -
P-180: Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study2021 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Douglas Weston Sborov, Muhamed Baljević, Brandi Reeves, Jacob P. Laubach, Yvonne Adeduni Efebera, Cesar Rodriguez, +15 more
3citations -
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Lori Ann Leslie, Gerardo Musuraca, Pau Abrisqueta, Joshua Brody, Jacob Haaber Christensen, Alexander Fosså, +8 more
2citations -
Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
Brendan Paul Hodkinson, Ashwini Kumar, Sheri Skerget, Gary E. Mason, Elizabeth Shearin, Hein Ludlage, +26 more
1citations -
POSTER: MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study2023 Clinical Lymphoma Myeloma & Leukemia article Medicine Multiple Myeloma Research and Treatments Open access
Nizar Jacques Bahlis, Christy Joy Samaras, Donna Ellen Reece, Michaël Sébag, Jeffrey Matous, Jesús G. Berdeja, +12 more
0citations